CERC - Cerecor shares rise 5% as mAb shows promise in small COVID-19 trial

CERC-002, a monoclonal antibody (mAB) from Cerecor (CERC), reduced respiratory failure and death in a small trial of hospitalized COVID-19 patients.Results, published as a preprint in medRxiv and not yet peer reviewed, found that 83.9% of patients with acute respiratory distress syndrome given CERC-002 were alive and free of respiratory failure through day 28 compared to 64.5% of patients on placebo.In addition, higher reductions of approximately 50% in mortality were observed for CERC-002 compared to placebo (7.7% vs 14.3% at day 28; and 10.8% vs 22.5% at day 60).Data also showed efficacy was highest in those 60 and older:  76.5% vs 47.1%.Last month, Cerecor signed a deal with Kyowa Kirin (KYKOF) granting the Japanese pharma worldwide rights to develop, manufacture and commercialize CERC-002.Cerecor shares are up 5% to $3.14 in afternoon trading.

For further details see:

Cerecor shares rise 5% as mAb shows promise in small COVID-19 trial